4594 — BrightPath Biotherapeutics Co Share News
0.000.00%
Table: Brightpath Biotherapeutics -2017/18 group results
Table: Brightpath Biotherapeutics - 9-MTH group results
Brief: BrightPath Biotherapeutics says exercise of options
Brief: BrightPath Biotherapeutics says exercise of options
Brief: BrightPath Biotherapeutics says exercise of options
Brief: BrightPath Biotherapeutics says exercise of options
Brief: BrightPath Biotherapeutics says exercise of options
Table: Brightpath Biotherapeutics - 6-MTH group results
Table: Brightpath Biotherapeutics -Q1 group results
Brief: BrightPath Biotherapeutics says collaboration with The University of Tokyo
Brief: GreenPeptide to change name to BrightPath Biotherapeutics Co Ltd
Table: Green Peptide -2016/17 group results
Table: Green Peptide -2016/17 parent results
Table: Green Peptide -2016/17 group forecast
Brief: GreenPeptide announces exercise of options
Table: Green Peptide -9-MTH group results
Table: Green Peptide -2016/17 group forecast
Brief: GreenPeptide announces exercise of options
Brief: GreenPeptide says initiation of a phase II clinical trial of the cancer peptide vaccine GRN-1201 in US